Τίτλος:
Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Orally administered iron can induce colonic inflammation in healthy animals and aggravate experimental colitis. Aim: To investigate the influence of the biologic agents infliximab and adalimumab on the severity of TNBS colitis following orally supplemented iron. Materials-Methods: 204 Wistar rats were allocated into 14 groups. Colitis was induced by TNBS. Iron was administered via a mouth catheter at a dose of 0.027, 0.3, and 3%/kg diet per day, respectively. Infliximab was subcutaneously administered on the 2nd and 6th day in a dose of 5 mg/kgBW, while adalimumab was administered on the 2nd day in a dose of 2 mg/kgBW. On the 8th day, all animals were euthanatized. Activity of colitis and extent of tissue damage were assessed histologically. Tissue Tumor Necrosis Factor-α (t-TNF-α) and malondialdehyde (t-MDA) were estimated. Results: In normal rats both agents significantly worsen the degree of inflammation induced by moderate or high iron supplementation despite the disappearance of t-TNF-α, and reduction of t-MDA. In the groups of TNBS colitis and moderate or high iron administration, both agents again significantly worsen the degree of inflammation despite the significant reduction in the t-TNF-α and t-MDA. Conclusion: Adalimumab and infliximab do not ameliorate the inflammation in TNBS-induced colitis aggravated by orally administered iron. These findings might be clinically relevant in patients with active IBD under concurrent treatment with biologic agents and per oral iron. Copyright © 2017 Taylor & Francis Group, LLC.
Συγγραφείς:
Triantafillidis, J.
Vagianos, C.
Agrogiannis, G.
Gikas, A.
Douvi, G.
Syrmos, N.
Patsouris, E.
Papalois, A.
Περιοδικό:
Journal of Investigative Surgery
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
adalimumab; infliximab; iron; malonaldehyde; trinitrobenzenesulfonic acid; tumor necrosis factor; adalimumab; antiinflammatory agent; infliximab; iron; malonaldehyde; trinitrobenzenesulfonic acid; tumor necrosis factor, animal experiment; animal model; animal tissue; Article; colon; controlled study; disease severity; drug effect; experimental colitis; histopathology; nonhuman; priority journal; rat; rat model; reduction (chemistry); anemia; animal; antagonists and inhibitors; chemically induced; disease model; drug effect; human; inflammatory bowel disease; intestine mucosa; male; metabolism; Wistar rat, Adalimumab; Anemia; Animals; Anti-Inflammatory Agents; Colon; Disease Models, Animal; Humans; Inflammatory Bowel Diseases; Infliximab; Intestinal Mucosa; Iron; Male; Malondialdehyde; Rats; Rats, Wistar; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha
DOI:
10.1080/08941939.2016.1215574
